Drug profile · INN
atorvastatin calcium
LYPQOZET
atorvastatin calcium (LYPQOZET) is a hmg-coa reductase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — atorvastatin calcium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 3
- Data quality
- 0.89
Quick answer
atorvastatin calcium (LYPQOZET) is a hmg-coa reductase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
HMG-CoA reductase inhibitor
Primary target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is atorvastatin calcium?
atorvastatin calcium (LYPQOZET) is a hmg-coa reductase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for atorvastatin calcium?
LYPQOZET is a marketed brand name for atorvastatin calcium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atorvastatin calcium?
atorvastatin calcium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.